Lung Cancer TALK: A Review of Data from the IASLC 2020 World Conference on Lung Cancer - Episode 4

WCLC Updates in Neoadjuvant Therapy for NSCLC

March 5, 2021
Stephen Liu, MD, Georgetown Lombardi Comprehensive Cancer Center

Sarah Goldberg, MD, MPH, Yale School of Medicine

Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center

Heather A. Wakelee, MD, Stanford University Medical Center

Experts in thoracic oncology discuss the role of single-agent immunotherapy as neoadjuvant therapy and comment on the viability of MPR [major pathologic response] as a surrogate endpoint for non–small cell lung cancer (NSCLC).

Data from the following clinical trial are discussed: 

  •  PS01.05 - Surgical and Clinical Outcomes With Neoadjuvant Atezolizumab in Resectable Stage IB–IIIB NSCLC: LCMC3 Trial Primary Analysis